Progressive Corp vs Tilray Brands Inc — how do they compare? Progressive Corp trades at $216.26 (market cap $124.88B), while Tilray Brands Inc trades at $4.21 (market cap $591.60M). The key difference: Progressive Corp is far larger — about 211.1× Tilray Brands Inc's market cap, and Progressive Corp pays a 0.19% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| PGR | TLRY | |
|---|---|---|
Market Cap | $124.88B | $591.60M |
Sector | Financials | Health |
52-Week High | $248.80 | $21.00 |
52-Week Low | $190.40 | $3.88 |
Enterprise Value | $133.09B | $758.73M |
Dividend Yield | 0.19% | — |
Signals from Pluang's Aura AI — not financial advice
Progressive (PGR) trades at $214.90, down 1.85% on the day, with a bearish technical signal and neutral oscillators. The stock shows strong fundamentals with a P/E of 10.78, net income margin of 12.85%, and consistent revenue growth from $49.6B in 2022 to $87.6B in 2025. Recent earnings beat expectations in Q2 2026, but Q1 2026 missed. News highlights competition in auto insurance and institutional buying, while July 2026 earnings declined year-over-year due to expenses.
The outlook is mixed: valuation appears attractive with growth potential, but technical weakness and competitive pressures pose risks. Analyst consensus is a buy with a $231.18 price target, though hold ratings dominate at 52.38%. Key risks include expense management and market volatility, while institutional accumulation supports sentiment.
TLRY trades at $4.30, down 4.44% today, reflecting ongoing investor skepticism despite record fiscal 2026 revenue of $915 million. The stock shows bearish technical signals with key support at $4.00, while fundamentals reveal significant challenges including negative net income margins (-13.26%) and consecutive earnings misses. Recent developments include strategic partnerships expansion in New York and California spirits markets and increased medical cannabis production capacity to 275 metric tonnes.
TLRY faces substantial execution risks with persistent losses and negative cash flow, though trading below book value (P/B 0.37) offers potential value. Analyst consensus remains cautious with 65% hold ratings, while regulatory progress in cannabis remains a key catalyst. The stock requires successful margin improvement and U.S. regulatory clarity for sustained recovery.
Trailing returns across standard periods
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →